Genetic Technologies Receives New York State Certification
Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce that it has received its Clinical Laboratory Permit from the New York State Department of Health ("DoH"). In late July, the Company's Melbourne laboratories were inspected under New York's DoH Clinical Laboratory
Evaluation Program ("CLEP") and, following the two-day audit, it subsequently received a Laboratory Evaluation Report with "No significant deficiencies".
Thus, the permit was able to be issued immediately.
This permit allows the Company to test BREVAGen™ from residents of New York State -- a densely populated state of nearly 20 million people -- and completes the out of state licensures allowing the Company to provide testing services to all 50 US states. The Company can now meet requests received from New York physicians to provide the BREVAGen™ test to patients as part of their clinical practice. Phenogen Sciences Inc. (Genetic Technologies' US subsidiary) will be appointing representatives in the near future to cover this state, with a particular emphasis on New York City.
The addition of this important territory will augment the current market adoption, which the Company notes is delivering significant increases in the number of test samples provided to the laboratory during the current quarter to date.
"This is a wonderful endorsement of the quality of our laboratory systems and the validation package provided by our highly qualified staff," said CEO, Ms. Alison Mew. "Importantly, it also allows women across the United States access to BREVAGen™ to deliver comprehensive breast health care."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.